Agios Pharmaceuticals, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Quarterly earnings reports show how the company is performing financially and guide investor expectations.
Public announcement of quarterly performance helps investors understand company progress and profitability.
Stock plan changes affect how employees are paid and can impact future share dilution for investors.
Quarterly earnings reports show how the company is performing financially and guide investor expectations.
Public announcement of quarterly performance helps investors understand company progress and profitability.
Annual reports provide comprehensive financial statements showing total yearly earnings and company health.
Public announcement of annual performance helps investors understand year-over-year company progress.
Stocky reads Agios Pharmaceuticals, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Agios Pharmaceuticals, Inc.'s most recent tracked filing was a 10-Q on 30 Jul 2026: Reports second quarter 2026 financial results and business highlights.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.